Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
CARLSBAD, Calif., Oct. 19, 2017 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release third quarter 2017 financial results after the close of trading on Thursday, November 2, 2017. The Company’s management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com. The call will be archived until Wednesday, November 15, 2017. The audio archive can be accessed by calling (877) 418-4766 in the U.S. or (614) 385-1253 from outside the U.S. The passcode for the audio replay is 97240039.
About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implant solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implant portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implant product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact
Lynn Pieper Lewis
415-937-5402
[email protected]
